Literature DB >> 11332289

Use of ML dipstick as a tool to classify leprosy patients.

S Buhrer-Sekula1, E N Sarno, L Oskam, S Koop, I Wichers, J A Nery, L M Vieira, H J de Matos, W R Faber, P R Klatser.   

Abstract

Leprosy control services face the problem of leprosy patients being misclassified by the lack of or the poor quality of skinsmear examination services. Misclassification increases the risk of relapse due to insufficient treatment if a multibacillary (MB) patient is classified as paucibacillary (PB), thereby also prolonging the time that the patient is infectious. The World Health Organization (WHO) recommends at present an alternative classification based on the number of skin lesions. Its reliability, however, has been questioned. Our investigation sought to determine the usefulness of the ML Dipstick, a simple field assay to detect IgM antibodies to phenolic glycolipid-I of Mycobacterium leprae, for the classification of leprosy patients in addition to lesion count. In this study, 264 leprosy patients were investigated. Of 130 patients with a positive bacterial index (BI), 19 (14.6%) had less than 6 lesions and would have been classified as PB. Out of 134 patients with a negative BI, 26 (19.4%) had 6 or more lesions and would have been classified as MB patients if the lesion counting system would apply. Thus, the classification based on the number of lesions only was found to be 85% sensitive and 81% specific (using the BI as the gold standard) at detecting MB cases among the studied population. Sensitivity would have increased if patients would have been classified according to a combination of the number of lesions and the dipstick result. In that case patients are classified as MB when they are either dipstick positive (N = 16), have more than 6 lesions (N = 43), or both (N = 94). Patients negative for both dipstick and number of lesions would have been classified as PB (N = 111). The classification based on the number of lesions alone left 19 BI-positive cases classified as PB, while the combination method of the ML Dipstick and number of lesions left only 8 BI-positive cases classified as PB (5 borderline, 2 borderline lepromatous and 1 tuberculoid), thus preventing undertreatment. The combination method of the ML Dipstick and lesion counting was found to be 94% sensitive and 77% specific, which is an improvement of 9% (chi-squared test, p = 0.025) in sensitivity compared to lesion counting only. The results of this study indicate that testing all patients initially classified by lesion counting as PB (48% in our study population) with the dipstick can significantly contribute to improved classification of leprosy patients for treatment purposes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11332289

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  12 in total

1.  Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection.

Authors:  Annemieke Geluk; Michèl R Klein; Kees L M C Franken; Krista E van Meijgaarden; Brigitte Wieles; Kelly Cristina Pereira; Samira Bührer-Sékula; Paul R Klatser; Patrick J Brennan; John S Spencer; Diana L Williams; Maria C V Pessolani; Elizabeth P Sampaio; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy.

Authors:  S Bührer-Sékula; H L Smits; G C Gussenhoven; J van Leeuwen; S Amador; T Fujiwara; P R Klatser; L Oskam
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

3.  Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.

Authors:  F Johannes Moet; David Pahan; Linda Oskam; Jan H Richardus
Journal:  BMJ       Date:  2008-03-10

4.  Rapid quantitative serological test for detection of infection with Mycobacterium leprae, the causative agent of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon; Armi Maghanoy; Florenda M Orcullo; Marjorie Cang; Ronaldo Ferreira Dias; Marco Collovati; Steven G Reed
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

5.  Pathogen-specific epitopes as epidemiological tools for defining the magnitude of Mycobacterium leprae transmission in areas endemic for leprosy.

Authors:  Marcia V S B Martins; Marjorie M da S Guimarães; John S Spencer; Mariana A V B Hacker; Luciana S Costa; Fernanda M Carvalho; Annemieke Geluk; Jolien J van der Ploeg-van Schip; Maria A A Pontes; Heitor S Gonçalves; Janvier P de Morais; Tereza J P G Bandeira; Maria C V Pessolani; Patrick J Brennan; Geraldo M B Pereira
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

6.  Nasal mucosa study of leprosy contacts with positive serology for the phenolic glycolipid 1 antigen.

Authors:  Ana Cristina da Costa Martins; Alice Miranda; Maria Leide Wan-del-Rey de Oliveira; Samira Bührer-Sékula; Alejandra Martinez
Journal:  Braz J Otorhinolaryngol       Date:  2010 Sep-Oct

7.  Genetic, household and spatial clustering of leprosy on an island in Indonesia: a population-based study.

Authors:  Mirjam I Bakker; Linda May; Mochammad Hatta; Agnes Kwenang; Paul R Klatser; Linda Oskam; Jeanine J Houwing-Duistermaat
Journal:  BMC Med Genet       Date:  2005-11-24       Impact factor: 2.103

8.  Development of a quantitative rapid diagnostic test for multibacillary leprosy using smart phone technology.

Authors:  Ludimila Paula Vaz Cardoso; Ronaldo Ferreira Dias; Aline Araújo Freitas; Emerith Mayra Hungria; Regiane Morillas Oliveira; Marco Collovati; Steven G Reed; Malcolm S Duthie; Mariane Martins Araújo Stefani
Journal:  BMC Infect Dis       Date:  2013-10-23       Impact factor: 3.090

9.  Preventing nerve function impairment in leprosy: validation and updating of a prediction rule.

Authors:  Ron P Schuring; Jan H Richardus; Ewout W Steyerberg; David Pahan; William R Faber; Linda Oskam
Journal:  PLoS Negl Trop Dis       Date:  2008-08-27

10.  Multibacillary leprosy patients with high and persistent serum antibodies to leprosy IDRI diagnostic-1/LID-1: higher susceptibility to develop type 2 reactions.

Authors:  Danielle de Freitas Mizoguti; Emerith Mayra Hungria; Aline Araújo Freitas; Regiane Morillas Oliveira; Ludimila Paula Vaz Cardoso; Mauricio Barcelos Costa; Ana Lúcia Maroclo Sousa; Malcolm S Duthie; Mariane Martins Araújo Stefani
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.